LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

Search

IQVIA Holdings Inc

Cerrado

SectorSanidad

168.34 2.19

Resumen

Variación precio

24h

Actual

Mínimo

164.66

Máximo

171.35

Métricas clave

By Trading Economics

Ingresos

182M

514M

Ventas

264M

4.4B

P/B

Media del Sector

21.054

61.417

Margen de beneficios

11.778

Empleados

93,000

EBITDA

1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+38.04% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-11B

29B

Apertura anterior

166.15

Cierre anterior

168.34

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

IQVIA Holdings Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2026, 22:42 UTC

Ganancias

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Ganancias

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Charlas de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Charlas de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Ganancias

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Ganancias

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Ganancias

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Ganancias

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Ganancias

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Ganancias

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

IQVIA Holdings Inc previsión

Precio Objetivo

By TipRanks

38.04% repunte

Estimación a 12 Meses

Media 227.62 USD  38.04%

Máximo 255 USD

Mínimo 200 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para IQVIA Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

14

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

150.68 / 153.45Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat